Latest Ratios: P/E Ratio -3.8x · EV/EBITDA N/A · ROE -94.8%. (2008–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $911M | $750M | $1.1B | $831M | $929M | $1.7B | $577M | $494M | $356M | $110M |
| Enterprise Value | $936M | $782M | $543M | $1.0B | $794M | $845M | $1.4B | $558M | $485M | $351M | $108M |
| P/E Ratio → | -3.77 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 15.77 | 13.50 | 13.93 | — | — | — | — | — | — | — | — |
| P/B Ratio | 6.04 | 5.23 | 1.81 | 2.65 | 1.98 | 1.83 | 2.84 | 2.64 | 3.07 | 4.45 | 1.94 |
| P/FCF | — | — | 5.61 | — | — | — | — | — | — | — | — |
| P/OCF | — | — | 5.59 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 11.59 | 10.07 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | 4.05 | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.9% | 99.9% | 100.0% | — | — | — | — | — | — | — | — |
| Operating Margin | -449.9% | -449.9% | -358.5% | — | — | — | — | — | — | — | — |
| Net Profit Margin | -412.9% | -412.9% | -322.9% | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -94.8% | -94.8% | -42.9% | -37.3% | -29.3% | -23.3% | -21.6% | -33.3% | -50.2% | -51.8% | -39.7% |
| ROA | -37.2% | -37.2% | -28.8% | -33.7% | -27.4% | -22.1% | -20.2% | -29.8% | -43.5% | -42.8% | -35.1% |
| ROIC | -181.3% | -181.3% | -49.7% | -32.7% | -26.1% | -27.2% | -27.5% | -28.7% | -41.4% | -41.6% | -35.1% |
| ROCE | -46.6% | -46.6% | -35.3% | -39.2% | -29.6% | -23.2% | -21.7% | -34.2% | -49.4% | -48.0% | -38.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.12 | 0.12 | 0.04 | 0.04 | 0.03 | 0.01 | 0.02 | 0.04 | 0.05 | 0.09 | 0.13 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.74 | -0.50 | -0.05 | -0.09 | -0.17 | -0.51 | -0.08 | -0.05 | -0.05 | -0.04 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | -1.55 | — | — | — | — | — | — | — | — |
| Interest Coverage | -183.11 | -183.11 | -105.22 | -97.54 | -592.19 | -314.14 | -154.06 | -116.34 | -64.83 | -40.63 | -49.16 |
Net cash position: cash ($149M) exceeds total debt ($20M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.06 | 6.06 | 9.46 | 12.26 | 18.56 | 23.26 | 24.49 | 15.39 | 13.31 | 9.43 | 12.62 |
| Quick Ratio | 6.05 | 6.05 | 9.46 | 12.26 | 18.56 | 23.26 | 24.49 | 15.39 | 13.31 | 9.43 | 12.62 |
| Cash Ratio | 5.70 | 5.70 | 9.24 | 12.02 | 18.21 | 23.07 | 24.34 | 15.22 | 13.15 | 9.29 | 12.44 |
| Asset Turnover | — | 0.09 | 0.07 | — | — | — | — | — | — | — | — |
| Inventory Turnover | 0.14 | 0.14 | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 68.17 | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | 17.8% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $88M | $86M | $73M | $67M | $66M | $53M | $42M | $35M | $23M | $19M |
Clinical trial binary outcome
According to current market data, Kura trades at a price-to-sales ratio of 14.34, a valuation that appears to heavily discount future success in the menin inhibitor space while ignoring the significant dilution risk inherent in its current cash-burning, non-commercial operational model.
The elevated P/S multiple suggests that investors are pricing in a high probability of regulatory approval for ziftomenib rather than current fundamental performance. This valuation is particularly aggressive given the lack of recurring revenue, implying that any delay in clinical trial readouts could lead to a sharp contraction in the stock's multiple.
Based on reported financial figures, Kura's ROIC has deteriorated to -85.3% in 2026Q1, reflecting a persistent trend of capital destruction as the firm aggressively funds clinical development without the offsetting benefit of commercial product margins to stabilize its return profile.
The consistent decline in ROIC highlights the extreme capital intensity required to advance the ziftomenib pipeline. Investors should monitor whether this trend reverses as the company moves toward potential commercialization, though current data suggests that capital efficiency remains secondary to the primary objective of clinical milestone achievement.
As reported in recent quarterly filings, Kura's current ratio has compressed from 16.67 in 2024Q1 to 6.15 in 2026Q1, signaling a significant reduction in the firm's liquidity cushion as it continues to fund intensive R&D operations through its existing cash reserves.
While a current ratio of 6.15 remains technically robust, the rapid downward trajectory indicates that the company is consuming its capital base at an unsustainable rate. This trend warrants close investigation, as the firm may be forced to seek dilutive financing if clinical milestones do not trigger further partnership payments.
As evidenced by the company's reliance on milestone-driven income, the P/S ratio is a fundamentally flawed metric for Kura, as it obscures the lumpy, non-recurring nature of partnership payments that do not represent the sustainable, high-margin commercial revenue typical of established pharmaceutical firms.
Investors should instead focus on cash runway and clinical trial enrollment velocity as more accurate proxies for value creation. Relying on P/S multiples in this context risks misinterpreting accounting-driven revenue recognition as evidence of operational scale, which is not currently supported by the firm's underlying business model.
Includes 30+ ratios · 18 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KURA stock.
Kura Oncology, Inc.'s current P/E ratio is -3.8x. This places it at the 50th percentile of its historical range.
Kura Oncology, Inc.'s return on equity (ROE) is -94.8%. The historical average is -43.8%.
Based on historical data, Kura Oncology, Inc. is trading at a P/E of -3.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Kura Oncology, Inc. has 99.9% gross margin and -449.9% operating margin.